Bayer Head Of Global Drug Discovery Andreas Busch: An Interview With "The Pink Sheet" DAILY (Part 2 Of 2)
This article was originally published in The Pink Sheet Daily
In part 2 of an interview with Busch, who oversees pharma R&D through proof-of-concept, the research exec talks about Bayer's plans to increase investment in R&D, the acquisition of Schering AG and Bayer's growing research presence in China.
You may also be interested in...
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.